Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Spok Holdings, Inc., through its subsidiary, Spok, Inc., engages in the healthcare communication solutions in the United States, Europe, Canada, Australia, Asia, and the Middle East. Its products and services enhance workflows for clinicians and support administrative compliance. The company delivers clinical information to care teams when and where it matters to enhance patient outcomes; and provides GenA Pager, a one-way alphanumeric pager. It offers subscriptions to one-way or two-way messaging services, as well as alphanumeric pagers that are configurable to support unencrypted or encrypted operation; and ancillary services, such as voicemail, and equipment loss or maintenance protection services, as well as sells devices to resellers who lease or resell them to their subscribers. The company provides Spok Care Connect suite products for contact centers, clinical alerting and notification, mobile communications and messaging, and public safety notifications. In addition, it provides professional, software license updates, and product support services, as well as sells third-party equipment. It serves businesses, professionals, management personnel, medical personnel, field sales personnel and service forces, members of the construction industry and construction trades, real estate brokers and developers, sales and services organizations, specialty trade organizations, manufacturing organizations, and government agencies. The company was formerly known as USA Mobility, Inc. and changed its name to Spok Holdings, Inc. in July 2014. Spok Holdings, Inc. was founded in 1986 and is headquartered in Plano, Texas.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $140M | $24M | $16M | $25M | 10.8% | 1.5% | 6.1% |
| 2024 | $138M | $24M | $15M | $26M | 9.7% | -1.0% | -4.5% |
| 2023 | $139M | $26M | $16M | $23M | 9.6% | 3.3% | -28.3% |
| 2022 | $135M | $11M | $22M | $3M | 12.8% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 134.53 | 139.02 | 137.65 | 139.71 |
| Operating Revenue | - | 134.53 | 139.02 | 137.65 | 139.71 |
| Cost Of Revenue | - | 28.27 | 27.09 | 28.71 | 29.78 |
| Gross Profit | - | 106.27 | 111.93 | 108.95 | 109.92 |
| Operating Expense | - | 98.70 | 90.13 | 88.88 | 89.76 |
| Research And Development | - | 13.62 | 10.68 | 11.69 | 12.22 |
| Selling General And Administration | - | 54.09 | 47.80 | 47.40 | 49.51 |
| Total Expenses | - | 126.97 | 117.22 | 117.58 | 119.54 |
| Operating Income | - | 7.57 | 21.80 | 20.07 | 20.17 |
| Total Operating Income As Reported | - | 0.24 | 21.23 | 18.96 | 19.71 |
| EBITDA | - | 11.14 | 26.30 | 24.22 | 23.60 |
| Normalized EBITDA | - | 18.47 | 26.87 | 25.32 | 24.06 |
| EBIT | - | 7.57 | 21.80 | 20.07 | 20.17 |
| Interest Income | - | 0.59 | 1.10 | 1.15 | 0.82 |
| Net Interest Income | - | 0.59 | 1.10 | 1.15 | 0.82 |
| Other Non Operating Income Expenses | - | 0.17 | 0 | -0.09 | 0.91 |
| Other Income Expense | - | -7.16 | -0.57 | -1.19 | 0.45 |
| Interest Income Non Operating | - | 0.59 | 1.10 | 1.15 | 0.82 |
| Net Non Operating Interest Income Expense | - | 0.59 | 1.10 | 1.15 | 0.82 |
| Pretax Income | - | 1 | 22.32 | 20.03 | 21.44 |
| Tax Provision | - | -20.86 | 6.66 | 5.07 | 5.56 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -1.54 | -0.17 | -0.28 | -0.12 |
| Net Income Continuous Operations | - | 21.86 | 15.67 | 14.96 | 15.88 |
| Net Income From Continuing And Discontinued Operation | - | 21.86 | 15.67 | 14.96 | 15.88 |
| Net Income From Continuing Operation Net Minority Interest | - | 21.86 | 15.67 | 14.96 | 15.88 |
| Net Income | - | 21.86 | 15.67 | 14.96 | 15.88 |
| Net Income Including Noncontrolling Interests | - | 21.86 | 15.67 | 14.96 | 15.88 |
| Normalized Income | - | 27.65 | 16.07 | 15.79 | 16.22 |
| Diluted NI Availto Com Stockholders | - | 21.86 | 15.67 | 14.96 | 15.88 |
| Basic Average Shares | - | 19.67 | 19.95 | 20.24 | 20.55 |
| Diluted Average Shares | - | 19.99 | 20.34 | 20.57 | 21.05 |
| Reconciled Depreciation | - | 3.57 | 3.84 | 3.45 | 3.34 |
| Reconciled Cost Of Revenue | - | 28.27 | 27.75 | 29.40 | 29.88 |
| Total Unusual Items | - | -7.33 | -0.57 | -1.10 | -0.46 |
| Total Unusual Items Excluding Goodwill | - | -7.33 | -0.57 | -1.10 | -0.46 |
| Special Income Charges | - | -7.33 | -0.57 | -1.10 | -0.46 |
| Write Off | 0.66 | 0.75 | 0.33 | - | - |
| Impairment Of Capital Assets | 15.66 | 0 | 0 | - | - |
| Restructuring And Mergern Acquisition | - | 7.33 | 0.57 | 1.10 | 0.46 |
| Depreciation Amortization Depletion Income Statement | - | 3.57 | 4.50 | 4.15 | 3.43 |
| Depreciation And Amortization In Income Statement | - | 3.57 | 4.50 | 4.15 | 3.43 |
| General And Administrative Expense | - | 37.80 | 31.06 | 31.18 | 31.80 |
| Other Gand A | - | 37.80 | 31.06 | 31.18 | 31.80 |
| Salaries And Wages | 43.88 | 38.76 | 36.43 | - | - |
| Rent Expense Supplemental | 22.80 | 21.26 | 18.76 | - | - |
| Other Operating Expenses | - | 27.41 | 27.14 | 25.64 | 24.60 |
| Selling And Marketing Expense | - | 16.30 | 16.75 | 16.22 | 17.70 |
| Rent And Landing Fees | 22.80 | 21.26 | 18.76 | - | - |
| Amortization | 5.77 | 0 | 0 | - | - |
| Amortization Of Intangibles Income Statement | 5.77 | 0 | 0 | - | - |
| Depreciation Income Statement | - | 2.89 | 4.50 | 4.15 | 3.43 |
| Other Taxes | 1.05 | 1.01 | 1.03 | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Spok Holdings, Inc.this co. | SPOK | $228M | 14.38 | 1.56 | 10.8% | 8.90 |
| Treace Medical Concepts, Inc. | TMCI | $239M | -4.06 | 2.74 | -67.6% | -6.98 |
| LifeMD, Inc. | LFMD | $236M | 16.41 | 10.17 | 62.0% | -135.17 |
| Arcturus Therapeutics Holdings Inc. | ARCT | $229M | -3.47 | 1.07 | -30.7% | -0.36 |
| LENZ Therapeutics, Inc. | LENZ | $226M |
| - |
| - |
| - |
| - |
| - |
| - |
| 0.79 |
| -28.9% |
| - |
| Fulcrum Therapeutics, Inc. | FULC | $225M | - | 0.64 | -21.5% | - |
| Foghorn Therapeutics Inc. | FHTX | $220M | -2.96 | -2.02 | 68.5% | -2.28 |
| Inhibikase Therapeutics, Inc. | IKT | $219M | -4.54 | 1.27 | -27.9% | -1.50 |
| Voyager Therapeutics, Inc. | VYGR | $219M | -1.83 | 1.12 | -61.1% | -1.49 |
| Peer Median | - | -3.21 | 1.09 | -28.4% | -1.89 | |
Historically, Jan has averaged the highest return (+3.9%); Mar the lowest (-6.3%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +4.4%Positive MonthJan 2026: +4.40% | -11.8%Negative MonthFeb 2026: -11.84% | -10.2%Negative MonthMar 2026: -10.21% | -1.9%Neutral MonthApr 2026: -1.93% | -0.9%Neutral MonthMay 2026: -0.94% | -3.3%Negative MonthJun 2026: -3.31% | +6.4%Positive MonthJul 2026: +6.45% | -3.9%*Negative MonthAug 2026: -3.85% | — | — | — | — |
| 2025 | +0.2%Neutral MonthJan 2025: +0.19% | +4.8%Positive MonthFeb 2025: +4.79% | -2.4%Negative MonthMar 2025: -2.43% | -12.8%Negative MonthApr 2025: -12.77% | +13.0%Positive MonthMay 2025: +12.97% | +9.1%Positive MonthJun 2025: +9.14% | +3.7%Positive MonthJul 2025: +3.73% | -1.0%Neutral MonthAug 2025: -0.98% | -5.0%Negative MonthSep 2025: -5.01% | -17.2%Negative MonthOct 2025: -17.16% | -7.1%Negative MonthNov 2025: -7.07% | -0.7%Neutral MonthDec 2025: -0.68% |
| 2024 | +7.0%Positive MonthJan 2024: +6.98% | +8.5%Positive MonthFeb 2024: +8.51% | -11.2%Negative MonthMar 2024: -11.24% | -3.1%Negative MonthApr 2024: -3.13% | -1.6%Neutral MonthMay 2024: -1.55% | -2.6%Negative MonthJun 2024: -2.63% | +3.5%Positive MonthJul 2024: +3.51% | -3.0%Negative MonthAug 2024: -3.00% | +1.3%Neutral MonthSep 2024: +1.28% | +3.4%Positive MonthOct 2024: +3.39% | +5.4%Positive MonthNov 2024: +5.39% | -2.2%Negative MonthDec 2024: -2.19% |
| 2023 | +2.0%Neutral MonthJan 2023: +1.95% | +19.6%Positive MonthFeb 2023: +19.64% | +1.4%Neutral MonthMar 2023: +1.40% | +20.7%Positive MonthApr 2023: +20.73% | -3.5%Negative MonthMay 2023: -3.52% | +12.6%Positive MonthJun 2023: +12.63% | +10.3%Positive MonthJul 2023: +10.31% | -2.9%Negative MonthAug 2023: -2.86% | +0.2%Neutral MonthSep 2023: +0.21% | +4.5%Positive MonthOct 2023: +4.48% | +12.4%Positive MonthNov 2023: +12.41% | -7.6%Negative MonthDec 2023: -7.64% |
| 2022 | +5.9%Positive MonthJan 2022: +5.89% | -11.3%Negative MonthFeb 2022: -11.34% | -8.9%Negative MonthMar 2022: -8.90% | -13.8%Negative MonthApr 2022: -13.78% | +2.2%Positive MonthMay 2022: +2.18% | -10.4%Negative MonthJun 2022: -10.38% | +4.9%Positive MonthJul 2022: +4.92% | +8.9%Positive MonthAug 2022: +8.93% | +6.1%Positive MonthSep 2022: +6.11% | +15.1%Positive MonthOct 2022: +15.05% | -7.6%Negative MonthNov 2022: -7.62% | +0.9%Neutral MonthDec 2022: +0.86% |
| 2021 | — | — | — | — | +13.6%Positive MonthMay 2021: +13.63% | -17.6%Negative MonthJun 2021: -17.57% | -14.3%Negative MonthJul 2021: -14.35% | +20.3%Positive MonthAug 2021: +20.27% | +3.1%Positive MonthSep 2021: +3.13% | +0.7%Neutral MonthOct 2021: +0.68% | -6.2%Negative MonthNov 2021: -6.22% | -3.3%Negative MonthDec 2021: -3.32% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
